THE ARISING · Markets & Strategy
Ionis Cuts Tryngolza Sales Forecast by Roughly Half
Ionis reported $9 million in third-quarter U.S. net product sales for Tryngolza and lowered its 2026 forecast to approximately $50 million.
Ionis now expects Tryngolza, its triglyceride-lowering drug, to bring in approximately $50 million in 2026 U.S. net product sales, according to its November 9 financial release. The company's earlier forecast was $100 million to $110 million. That is a cut of roughly half.
Third-quarter U.S. net product sales were $9 million, bringing the first nine months of 2026 to $41 million. Ionis attributed the lower forecast to a more gradual launch ramp than anticipated.
For investors, the episode is a reminder of how much an early sales path can matter. Peak-sales estimates for new drugs rest on assumptions about how quickly clinicians adopt them.
Ionis said it remained confident in Tryngolza's long-term growth potential and multibillion-dollar peak sales. Those are company expectations, not achieved revenue.
Whether Ionis reports prescriptions rising in coming quarters, and whether its long-term sales expectations change.